Roger G. Stoll, Ph.D. has over 30 years of experience in the pharmaceutical, medical devices, and diagnostic industries. Most recently, he was the Executive Vice President of Fresenius Medical Care – N. America, in charge of both the dialysis products and laboratory services. Dr. Stoll oversaw the company’s manufacturing, sales, service, research and development, and business development functions, and was responsible for combined sales of approximately $900 million as well as more than 3,000 employees. From 1991 to 1998, Dr. Stoll was CEO of Ohmeda, Inc., a worldwide leader in anesthesia and critical care products with sales of approximately $1 billion and more than 5,000 employees. From 1986 to 1991, Dr. Stoll held several positions within Bayer, AG. Initially at Bayer, he had responsibilities that included being President of the Consumer Health Care Group of Miles. He then became the Executive Vice President and General Manager of the Diagnostics Business Group of Bayer, during which time the business expanded from $400 million to approximately $1 billion in sales. Before 1986, Dr. Stoll held positions of increasing responsibility including President of the American Critical Care Division of American Hospital Supply Corporation (now Baxter International) and in clinical research at The Upjohn Company. In addition to the Cortex board, Dr. Stoll currently serves as a member of the boards of directors of Agensys, Inc., Questcor Pharmaceuticals, Inc., and LifePoint, Inc. Dr. Stoll obtained a B.S. in Pharmacy from Ferris State University and a Ph.D. in Biopharmaceutics from the University of Connecticut.
Additional recommended knowledge
He currently is Chairman of the Board for Cortex Pharmaceuticals, leading up research on experimental drug CX717